Back to search results

Oral Supplement for Rosacea and Inflammation

This study is looking at how an oral supplement containing L-Histidine and antioxidants might help people with rosacea. Rosacea is a long-lasting skin condition that can cause redness and bumps, and it's linked to inflammation and problems with the skin's protective barrier. This research aims to see if taking the Skin Barrier Oral Supplement can improve your skin and gut health, and reduce overall inflammation. You might be able to join if you are 30 to 70 years old, have mild to moderate rosacea, and a specific blood marker (hs-CRP) that is 1.0 mg/L or higher. The study will measure changes in your skin's barrier function (Transepidermal water loss, or TEWL) and blood inflammation levels (hs-CRP) after 8 weeks. The current recruitment status is unclear, and they plan to enroll 24 participants.

Study design
This is an interventional study planning to enroll 24 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements for this study are taken at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06072066

Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea

Recruiting
NAAges 30–70InterventionalTreatment
Integrative Skin Science and Research
~24 participants
Updated 2024-08-27 on ClinicalTrials.gov
What's tested:Skin Barrier Oral Supplement

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Transepidermal water loss (TEWL)
Measured over 8 weeks
+1 more outcome measured

Conditions

Rosacea
Systemic Inflammation

Explore related trials

Rosacea

Where it's being run

1 sites across 1 states
California1

Who to contact

Caitlin Egli
[email protected]
916-750-2463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Males and females 30 to 70 years of age
The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)
High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L

Exclusion

The presence of severe rosacea as noted by the investigator global assessment.
Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment
Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.
Those who are unwilling to keep their facial regimen the same throughout the study.
Individuals who have been on an oral antibiotic within the previous one month.
Individuals who are pregnant or breastfeeding.
Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.
Individuals on oral contraceptive pills or progesterone or estrogen containing therapies.
Use of isotretinoin within the three months prior to enrollment.
Individuals on finasteride or dutasteride
Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.

What this trial measures

  • Transepidermal water loss (TEWL)8 weeks

    Change in the facial transepidermal water loss (TEWL) using the Vapometer.

  • Blood hs-CRP level8 weeks

    Change in blood hs-CRP level through blood spot testing